Nitric oxide (NO) is a biological mediator which is synthesized from L-arginine by a family of nitric oxide synthases (NOS). We have studied the expression of the inducible NOS (iNOS) by bone marrow cells from the patients with myelodysplastic syndromes (MDS) at the mRNA level by RT-PCR assay and at the protein level by immunohistochemical staining using a specific anti-iNOS monoclonal antibody. The iNOS message was present in 92% of bone marrow tissues from MDS patients (11 out of 12) by an examination using RT-PCR. Basically, iNOS message was negative or very weak in control (1/9) and AML (0/7) cases. This was supported by immunohistochemical findings that the iNOS was positive in most of the bone marrow samples from MDS patients (9 out of 12), while bone marrow cells of control (0 out of 12) and AML (0 out of 5) cases were basically negative. Double immunostaining for CD68 antigen, which is a marker for macrophage lineage cells, and iNOS was performed on MDS bone marrow sections. iNOS was dominantly localized to bone marrow macrophages, although a part of myeloid cells were also positively stained with anti-iNOS antibody in a part of cases. These results indicated that there is some in vivo induction of iNOS expression for local NO production that might be involved in the dysregulation of hematopoiesis in bone marrow of MDS.
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies affecting mainly the middle aged and elderly. [1] [2] [3] [4] The majority of affected patients die within 1-2 years due to overt leukemic transformation or the complication of cytopenias. The development of cytopenias despite the presence of cellular marrow is thought to be due to ineffective hematopoiesis probably associated with frequent apoptosis of hematopoietic cells. 5, 6 The Fas antigen, as well as Fas-ligand, was over-expressed by bone marrow cells of MDS patients. 6 The expression of Fas antigen by hematopoietic cells would result in the induction of apoptosis of these cells. In vitro examination revealed that the proliferation, as well as death, of hematopoietic cells is regulated by various proteins with stimulatory and inhibitory activities. 1 Colony-stimulating factors (CSFs) [7] [8] [9] [10] and several cytokines [8] [9] [10] [11] [12] are known to have proliferative effects on hematopoietic progenitor cells, while several substances such as tumor necrosis factor (TNF) 8, 9, [13] [14] [15] and interferons (IFNs) 14 were demonstrated to inhibit hematopoietic cell growth. Although the exact function of these substances in vivo has not yet been elucidated, overexpression of certain soluble factors by bone marrow cells may disrupt hematopoiesis by exerting profound inhibitory effects on hematopoietic progenitor cells. We have previously demonstrated that the expression of TNF-␣ and IFN-␥ was up- 16 In MDS bone marrow, TNF-␣, as well as IFN-␥, was mainly localized to the stromal cells, such as bone marrow macrophages. Therefore not only the proliferation of MDS clone cells but also the abnormal function of stromal cells of the bone marrow may be involved in mechanisms causing cytopenias in MDS through disturbed regulation of the expression and production of growth factors and cytokines.
Induction of nitric oxide synthase (NOS) and production of the toxic metabolite nitric oxide (NO) is one of the TNF-␣ and IFN-␥ regulated effector mechanisms that can lead to apoptosis of hematopoietic progenitor cells. 17 Fas-receptor (FAS) expression can be stimulated by TNF-␣ and IFN-␥. It has been shown that transactivation of inducible NOS (iNOS), and possibly Fas promotors, by interferon regulatory factor-1 expressed in response to IFN-␥ may be a part of the iNOS transduction pathway. This study therefore attempted to investigate the disturbed regulatory mechanisms of hematopoiesis in MDS in vivo by defining up-regulation of iNOS production using RT-PCR and then to immunohistochemically demonstrate the localization of the iNOS producing cells in the bone marrow.
Materials and methods

Patients
Bone marrow samples of trephin biopsy and partly autopsy material were taken from 14 patients with MDS; three with refractory anemia (RA), one with RA with ring sideroblasts (RARS), four with RA with excess of blasts (RAEB), four with RAEB in transformation (RAEB-T) and two with chronic myelomonocytic leukemia (CMMoL). The samples were embedded in OCT compound (purchased from Sakura, Tokyo, Japan), frozen using liquid nitrogen, cryosectioned and investigated for the expression of iNOS. A diagnosis of MDS was based on FAB criteria. 1 None of the patients had received specific therapeutic agents prior to the study. The range of age in MDS patients was 44-83 (60.8 ± 11.6, mean ± s.d.) and male:female ratio was 10:4. Bone marrow samples from 15 individuals with no hematological disorders were used as controls (age range 21-84, mean ± s.d., 62.1 ± 17.1; male:female, 10:5) and additionally, seven patients with de novo AML (M2 or M4 by FAB classification, age range 56-76, mean ± s.d., 66.6 ± 7.3; male:female, 6:1) were also analyzed.
Preparation of RNA samples and amplification method
RNA was isolated from frozen bone marrow samples by a guanidium isothiocyanate solubilization/LiCl precipitation procedure. Tissue RNA (100 ng) was used as a template for the amplification reactions. Oligonucleotides as specific primers and probes for iNOS were synthesized by a commercial laboratory (Life Technologies Oriental, Tokyo, Japan). As a control reaction of PCR, ␤-actin was also detected in each run. The sequences of primers were as follows: iNOS: 5Ј PCR primer CGGTGCTGTATTTCCTTACGAGGCGAAGAAGG, 3Ј PCR primer GGTGCTACTTGTTAGGAGGTCAAGTAAAG-GGC; ␤-actin: 5Ј PCR primer AAGAGAGGCATCCTCACCCT, 3Ј PCR primer TACATGGCTGGGGTGTTGAA. The expected sizes of the PCR products were 257 bp for iNOS and 218 bp for ␤-actin. Complementary (c) DNA was synthesized by using Rous-associated virus reverse transcriptase (Takara Biomedicals, Kyoto, Japan). The PCR reaction was performed as described elsewhere. [18] [19] [20] Briefly, 100 ng of the RNA was used for RT-PCR. For cDNA synthesis, 100 ng in 4 l of sample RNA solution was heated at 65°C for 5 min and cooled rapidly. After adding 20 U of ribonuclease inhibitor (Takara), 1 l of 1.25 mm dNTP (dATP, dCTP, dGTP, dTTP, Pharmacia, Uppsala, Sweden) and 20 U of Rous-associated virus reverse transcriptase (Takara), the mixture was incubated at 40°C for 30 min, then heated at 94°C for 5 min and cooled rapidly. The PCR reaction mixture contained 10 l of cDNA, 10 l of 10 × PCR buffer, 11 l of 20 mm MgCl 2 , 16 l of 1.25 m dNTP, 42.5 l of DEPC-water, 100 pm 5Ј-and 3Ј-primer, and 2.5 U of thermostable Taq polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). The amplification was achieved with a DNA thermal cycler (Perkin Elmer Cetus). After denaturing at 94°C for 10 min, the amplification was conducted for 35 cycles at 94°C for 30 s, 55°C for 30 s and 72°C for 60 s. This was followed by re-extension for 10 min at 72°C. Ten-l aliquots of the product samples were analyzed by electrophoresis on a 1.8% agarose gel and visualized by UV fluorescence after staining with ethidium bromide. X174/HaeIIIcut DNA was run in parallel as a molecular weight marker. Then the density of bands was measured by scanning imager, Image Quant (Molecular Dynamics, Sunnyvale, CA, USA).
Immunohistochemistry
To examine the distribution of iNOS-producing cells in the bone marrow, polyclonal rabbit antibodies against iNOS (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were applied on frozen sections. Sections were then incubated with fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG antibody (DAKO, Glostrup, Denmark). On the same sections, the distribution of bone marrow macrophages was determined by double immunostaining with anti-CD68 antibody (KP-1, DAKO). This was followed by incubation with tetramethyl rhodamine isothiocyanate (TRITC)-conjugated anti-mouse IgG (DAKO). Control procedures included the substitution of equivalent concentrations of heavy chain-matched monoclonal antibody of irrelevant specificity and the staining of bone marrow sections from control as well as AML and CML cases. 6-11) . An RT-PCR reaction for ␤-actin (218 bp) was performed as an internal control, and positive signals were observed in all the samples examined.
Results
Expression of mRNA for iNOS in the bone marrow
So as to examine very low levels of iNOS mRNA expression in bone marrow cells, RT-PCR was performed using RNA from frozen bone marrow tissues. This method revealed the expression of iNOS mRNA, as defined by a 257 bp PCR product, in the bone marrow from patients with MDS. Control cases as well as AML and CML cases showed no expression or very weak expression of iNOS (Figure 1) . The frequency of up-regulation of iNOS mRNA in bone marrow samples is summarized in Table 1 . Most of the MDS cases expressed iNOS mRNA (11/12, 92%), while the majority of control (8/9) and all of the AML (7/7) samples did not show signal. Only one control case showed a very weak band indicating a low level of iNOS expression. Differences in the frequency of iNOS expression were statistically significant between MDS and control cases (Fisher's exact test, P Ͻ 0.001). However, because very weak bands were observed in part of the control cases, we measured the density of bands for iNOS as well as ␤-actin and calculated the ratio of the density iNOS/␤-actin. In control cases, the ratio was 0.09 ± 0.03 (mean ± s.e.m.), while the ratio was 10.3 ± 7.4 in MDS cases. Difference was significant by Student's t-test (P Ͻ 0.01).
Localization of iNOS in the bone marrow of MDS patients
As the mRNA of iNOS was overexpressed in the bone marrow of MDS patients, distribution of iNOS producing cells was examined by immunohistochemical method. As shown in Fig- antigen, a marker for macrophagelineage cells, was performed on the frozen bone marrow sections. The staining clarified that the iNOS producing cells were basically CD68-positive suggesting that these cells were mainly of bone marrow macrophage lineage (Figure 2b and c) .
The majority of iNOS strongly positive cells were also CD68-positive as indicated by yellow arrowheads in Figure 2c . However, not all of the CD68-positive cells were positive with antiiNOS immunostaining. The CD68 single positive cells were indicated by red arrowheads in Figure 2c . In some cases, iNOS was also positively stained in medium-sized round cells suggesting that part of the myeloid cells were also producing iNOS. 14 Recently, an increased frequency of apoptosis was observed in bone marrow cells of MDS patients. To clarify the mechanism of apoptosis induced in MDS, several in vivo studies were performed to elucidate the influence of several of the growth factors. They have indicated that TNF-␣ and IFN-␥ would be the major cytokines that evoke apoptosis of hematopoietic cells probably via the Fas/Fas-ligand pathway. 6, 28, 29 TNF-␣ and IFN-␥ suppress hematopoietic progenitor cell proliferation 30-32 and have been implicated in the mechanism of bone marrow failure. [33] [34] [35] For example in aplastic anemia, aberrant production of IFN-␥ and upregulation of TNF in bone marrow likely induce apoptosis of hematopoietic stem cells and progenitor cells. 33, 34 TNF-␣ and IFN-␥ are known to suppress both early and late stages of hematopoiesis and induce programmed cell death. 17 However, factors linking abnormal cytokine production of MDS bone marrow and an event of cell death have been still unclear.
Discussion
Nitric oxide has recently gained attention as a new class of molecule that serves as a variety of functions in different tissues. [36] [37] [38] Nitric oxide is synthesized by the oxidation of larginine by a family of NO synthases (NOSs). When normal bone marrow or CD34 + cells were exposed to NO, inhibition of colony formation was dose-dependent and direct. 39 Macrophages express iNOS in response to inflammatory stimuli such as TNF-␣, IFN-␥ or endotoxin. 40 Involvement of TNF-␣ and IFN-␥ in the regulation of NO production suggested that NO may influence the function of bone marrow cells and may be relevant for understanding the pathophysiology of hematologic diseases. The present study showed that bone marrow cells expressed iNOS in MDS patients. Our previous data have shown that TNF-␣, IFN-␥, Fas antigen and Fas-ligand were over-expressed in the bone marrow of MDS patients. Together with these findings we can speculate that disturbance in regulation of hematopoiesis including excess of apoptosis in the bone marrow cells of MDS may result from upregulation of TNF-␣ and IFN-␥ expression followed by iNOS production and then, by strong expression of Fas antigen in hematopoietic cells.
As to the localization of iNOS in the bone marrow cells of MDS, we could demonstrate that the major source of iNOS production may be macrophage lineage cells. Other than macrophages, iNOS have also been demonstrated in CD34 + cells, myeloid cells and megakaryocytes in the bone marrow. 39, 41 However, expression of iNOS has been well documented in macrophages when the cells were stimulated with cytokines such as TNF and IFNs. [42] [43] [44] The enhanced expression of NO production may be toxic to the surrounding cells or autotoxic. In the bone marrow of MDS patients, stromal cells could release NO in a paracrine fashion causing apoptosis of surrounding hematopoietic cells. Thus, induction of NO release by bone marrow stromal cells in vivo may have pathophysiologic implications on the regulation of bone marrow function such as apoptosis of hematopoietic cells of MDS cases.
